PharmaLex Group has completed the acquisition of ERA Consulting (ERA).
Founded in 1987, ERA is an international consulting firm which provides strategic product development and regulatory support and specializes in the development of vaccines, ATMPs and cell and gene therapies. They have offices in Germany, the UK and Australia, and a multidisciplinary team in the fields of molecular and cell biology, protein biochemistry, immunology, ATMPs, cell and gene therapy, non-clinical toxicology, manufacture, quality control, validation, and electronic submissions.
The acquisition also expands global geographical footprint and market reach, with a new location in Australia.
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers
from Pharmaceutical Outsourcing – all delivered right to your inbox! Sign up now!
“The ERA team is excited about being part of the PharmaLex Group, as this enables us to provide additional support to our clients through the breadth of PharmaLex’s services”, said Andrew Moore, Chief Operating Officer, ERA.
“The addition of ERA to the PharmaLex Group represents a key milestone in the company’s strategic orientation as solution provider for the biotech sector. ERA’s extensive expertise will add significant value to further build our biopharma solutions.”, said Dr. Thomas Dobmeyer, CEO PharmaLex. “Expanding our global network into Australia is also an important step and will help us strengthen our Asia-Pacific reach”, he concluded.